Previous 10 | Next 10 |
DUBLIN, Ireland and TREVOSE, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...
Strongbridge Biopharma, Inc (SBBP) Q4 2018 Results Earnings Conference Call February 26, 2019, 08:30 AM ET Company Participants Lindsay Rocco - Elixir Health Public Relations Matthew Pauls - President and CEO Fred Cohen - Chief Medical Officer Brian Davis - Chief Financial Offi...
Strongbridge Biopharma (NASDAQ: SBBP ): Q4 Non-GAAP EPS of -$0.46 beats by $0.03 ; GAAP EPS of $1.64 beats by $2.13 . More news on: Strongbridge Biopharma, Earnings news and commentary, Healthcare stocks news, , Read more ...
~ RECORLEV™ (levoketoconazole) Phase 3 Clinical Program and Type C FDA Meeting in First Quarter Progressing as Planned ~ ~ $145 Million Upfront Cash Payment and $36.7 Million Equity Investment from Novo Nordisk in Fourth Quarter 2018 Significantly Strengthened Company’s ...
DUBLIN, Ireland and TREVOSE, Pa., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced th...
DUBLIN, Ireland and TREVOSE, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...
Strongbridge Biopharma (SBBP) is a relatively under-the-radar company that really first came to our attention after it closed the Macrilen deal with Novo Nordisk (NVO) recently. That was a really solid deal that saw the stock go up 30+% in a day, and the company ended up with a lot of cash and...
In Vitro Data Show Preliminary Evidence That Levoketoconazole Inhibits ACTH Secretion and May Have Anti-Tumor Effect on Pituitary Adenoma Cells First Study in Primary Human Adrenal Cells Suggests Levoketoconazole, the Pure 2S,4R Enantiomer of Ketoconazole, May Be a More Potent Inhibit...
DUBLIN, Ireland and TREVOSE, Pa., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...
Strongbridge Biopharma, Inc (SBBP) Q3 2018 Earnings Conference Call October 31, 2018 09:15 AM ET Executives Lindsay Rocco - Elixir Health Public Relations Matthew Pauls - President and CEO Dr. Fred Cohen - Chief Medical Officer Brian Davis - Chief Financial Officer Analysts ...
News, Short Squeeze, Breakout and More Instantly...
Strongbridge Biopharma plc Company Name:
SBBP Stock Symbol:
NASDAQ Market:
Strongbridge Biopharma plc Website:
DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed a...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that the High Court of Ireland (the “ Court ”) has set the dat...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that its shareholders have voted to approve the previously announced proposed ac...